Literature DB >> 19933802

Mode of action of Van-M-02, a novel glycopeptide inhibitor of peptidoglycan synthesis, in vancomycin-resistant bacteria.

Kenji Miura1, Hidenori Yamashiro, Kouichi Uotani, Satoshi Kojima, Takashi Yutsudo, Jun Lu, Osamu Yoshida, Yoshinori Yamano, Hideki Maki, Hirokazu Arimoto.   

Abstract

Van-M-02, a novel glycopeptide, was revealed to exert potent activities against Gram-positive bacteria, including vancomycin-resistant enterococci (VRE) and vancomycin-resistant Staphylococcus aureus (VRSA). A crude assay system was then used to study the mode of action of Van-M-02 as a peptidoglycan synthesis model of both vancomycin-susceptible and -resistant strains. The results suggested that Van-M-02 inhibits the synthesis of lipid intermediates irrespective of their termini. This inhibitory activity may contribute to the anti-VRE and anti-VRSA activities observed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933802      PMCID: PMC2812124          DOI: 10.1128/AAC.00927-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus.

Authors:  H Maki; K Miura; Y Yamano
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Synthesis of rigidly-linked vancomycin dimers and their in vivo efficacy against resistant bacteria.

Authors:  Jun Lu; Osamu Yoshida; Sayaka Hayashi; Hirokazu Arimoto
Journal:  Chem Commun (Camb)       Date:  2006-10-24       Impact factor: 6.222

3.  Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.

Authors:  S S Rotun; V McMath; D J Schoonmaker; P S Maupin; F C Tenover; B C Hill; D M Ackman
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

4.  Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in Bacillus subtilis and Staphylococcus aureus.

Authors:  N Fairweather; S Kennedy; T J Foster; M Kehoe; G Dougan
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

5.  Staphylococcus aureus resistant to vancomycin--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-05       Impact factor: 17.586

Review 6.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

7.  In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus.

Authors:  Tanja Schneider; Maria Magdalena Senn; Brigitte Berger-Bächi; Alessandro Tossi; Hans-Georg Sahl; Imke Wiedemann
Journal:  Mol Microbiol       Date:  2004-07       Impact factor: 3.501

8.  Acute infection of mice with Smith strain of Staphylococcus aureus.

Authors:  G A HUNT; A J MOSES
Journal:  Science       Date:  1958-12-19       Impact factor: 47.728

9.  Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus.

Authors:  Marie-Laure Foucault; Patrice Courvalin; Catherine Grillot-Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

10.  Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

Authors:  Dawn M Sievert; James T Rudrik; Jean B Patel; L Clifford McDonald; Melinda J Wilkins; Jeffrey C Hageman
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

  10 in total
  3 in total

1.  Deciphering the mode of action of cell wall-inhibiting antibiotics using metabolic labeling of growing peptidoglycan in Streptococcus pyogenes.

Authors:  Atsushi Sugimoto; Asuka Maeda; Kaori Itto; Hirokazu Arimoto
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

2.  Screening for FtsZ Dimerization Inhibitors Using Fluorescence Cross-Correlation Spectroscopy and Surface Resonance Plasmon Analysis.

Authors:  Shintaro Mikuni; Kota Kodama; Akira Sasaki; Naoki Kohira; Hideki Maki; Masaharu Munetomo; Katsumi Maenaka; Masataka Kinjo
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

3.  Staphylococcus aureus Penicillin-Binding Protein 2 Can Use Depsi-Lipid II Derived from Vancomycin-Resistant Strains for Cell Wall Synthesis.

Authors:  Jun Nakamura; Hidenori Yamashiro; Hiroto Miya; Kenzo Nishiguchi; Hideki Maki; Hirokazu Arimoto
Journal:  Chemistry       Date:  2013-07-19       Impact factor: 5.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.